# EKR Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ekr-therapeutics

- Industry: Healthcare
- Headquarters: Bedminster, US
- Website: www.ekrtx.com
- Total disclosed funding: $68M
- Latest round: Series D (Mar 10, 2008)
- Investors on record: 6

## About

Founded in 2006, EKR is a specialty pharmaceutical company led by a seasoned team of industry professionals whose mission is to better patient outcomes in the hospital setting.

## Funding rounds

- Series D, Mar 10, 2008, $50M — LLR Partners, Quaker Partners Management, NewSpring, ESP Equity Partners, MPM BioImpact
- Series C, Aug 15, 2007, $13M — Quaker Partners Management, NewSpring, ESP Equity Partners, Merrill Lynch Ventures
- Series B, Jun 27, 2006, $5M — NewSpring, ESP Equity Partners

## Investors

- NewSpring (https://capitalatlas.ai/funds/newspring) — Series B, Series C, Series D
- ESP Equity Partners (https://capitalatlas.ai/funds/esp-equity-partners) — Series B, Series C, Series D
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series C, Series D
- Merrill Lynch Ventures — Series C
- LLR Partners (https://capitalatlas.ai/funds/llr-partners) — Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series D